2021
Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes. Journal Of The American Heart Association 2021, 10: e021084. PMID: 33998258, PMCID: PMC8403287, DOI: 10.1161/jaha.121.021084.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Drug UtilizationEligibility DeterminationFemaleGlucagon-Like Peptide-1 ReceptorGuideline AdherenceHeart Disease Risk FactorsHumansIncretinsMaleMiddle AgedNutrition SurveysPractice Guidelines as TopicPractice Patterns, Physicians'Risk AssessmentSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeUnited StatesConceptsSGLT-2 inhibitorsType 2 diabetes mellitusAtherosclerotic cardiovascular diseaseChronic kidney diseaseLarge clinical trialsGLP-1RAsDiabetes mellitusCardiovascular diseaseHeart failureKidney diseaseClinical trialsHigh-risk atherosclerotic cardiovascular diseaseGLP-1RA useAmerican Diabetes AssociationNutrition Examination SurveyAnti-hyperglycemic agentsPublic health benefitsComplex survey designCardiovascular riskGuideline recommendationsDiabetes AssociationExamination SurveyProtective therapyNational HealthAmerican College
2016
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care 2016, 40: 468-475. PMID: 27659408, PMCID: PMC5360291, DOI: 10.2337/dc16-0985.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug UtilizationFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinLogistic ModelsMaleMetforminMiddle AgedRetrospective StudiesSulfonylurea CompoundsThiazolidinedionesYoung AdultConceptsGlycemic controlSevere hypoglycemiaOlder patientsDipeptidyl peptidase-4 inhibitorsGlucose-lowering drugsGlucose-lowering medicationsProportion of patientsOverall glycemic controlPeptidase-4 inhibitorsMedicare Advantage patientsSex-standardized ratesType 2 diabetesOverall rateClass of agentsMore comorbiditiesChronic comorbiditiesYounger patientsAdvantage patientsDrug utilizationClaims dataPatientsHypoglycemiaHemoglobin AT2DMComorbidities
2015
Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures
Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, Ho PM, Eapen ZJ, Hernandez AF, Heidenreich PA, Bhatt DL, Peterson ED, Krumholz HM. Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation 2015, 132: 1347-1353. PMID: 26316616, PMCID: PMC4941099, DOI: 10.1161/circulationaha.115.014281.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBody Mass IndexCardiovascular AgentsComorbidityContraindicationsCross-Sectional StudiesDrug HypersensitivityDrug PrescriptionsDrug SubstitutionDrug Therapy, CombinationDrug UtilizationEvidence-Based MedicineFemaleGuideline AdherenceHeart FailureHospitalsHumansMaleMedication AdherenceMiddle AgedPatient AdmissionPatient DischargePolypharmacyPractice Guidelines as TopicQuality Assurance, Health CareConceptsHF quality measuresHydralazine/isosorbide dinitrateAngiotensin receptor blockersMedication groupHeart failureAldosterone antagonistsReceptor blockersMedication regimenIsosorbide dinitrateNew medicationsΒ-blockersEnzyme inhibitorsGuideline-directed medical therapyInitiation of angiotensinPrimary discharge diagnosisQuarter of patientsPatient's medication regimenHospital quality measuresAdequate prescribingMedication initiationHospital dischargeHospital admissionMedical therapyGuideline recommendationsDischarge diagnosis
2014
Age-specific gender differences in early mortality following ST-segment elevation myocardial infarction in China
Zheng X, Dreyer RP, Hu S, Spatz ES, Masoudi FA, Spertus JA, Nasir K, Li X, Li J, Wang S, Krumholz HM, Jiang L. Age-specific gender differences in early mortality following ST-segment elevation myocardial infarction in China. Heart 2014, 101: 349. PMID: 25510395, PMCID: PMC4453015, DOI: 10.1136/heartjnl-2014-306456.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAge FactorsAgedAged, 80 and overChinaDrug UtilizationFemaleHospital MortalityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRetrospective StudiesRural PopulationSex FactorsUrban PopulationConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionGender-age interactionHospital mortalityEarly mortalityMyocardial infarctionChina PEACE-Retrospective AMI StudyHospital mortality rateYears of ageAge-specific gender differencesPatient characteristicsHospital characteristicsMultivariable modelMortality rateGender differencesChinese populationMortalityYounger groupChinese hospitalsWomenAMI studyMenInfarctionAgeRepresentative sampleUse of Intravenous Diuretics on Day of Discharge in Adults Hospitalized for Heart Failure
Fazel R, Strait KM, Bikdeli B, Dharmarajan K, Krumholz HM. Use of Intravenous Diuretics on Day of Discharge in Adults Hospitalized for Heart Failure. Journal Of Cardiac Failure 2014, 20: 706-707. PMID: 24951932, PMCID: PMC4427892, DOI: 10.1016/j.cardfail.2014.06.354.Peer-Reviewed Original ResearchRole of Nicotinic Acid in Atherosclerosis Prevention—Reply
Jackevicius CA, Krumholz HM. Role of Nicotinic Acid in Atherosclerosis Prevention—Reply. JAMA Internal Medicine 2014, 174: 649-649. PMID: 24711201, DOI: 10.1001/jamainternmed.2013.12811.Peer-Reviewed Original ResearchCaution Warranted When Defining Contraindications in Initiating β-Blocker Therapy—Reply
Dharmarajan K, Krumholz HM. Caution Warranted When Defining Contraindications in Initiating β-Blocker Therapy—Reply. JAMA Internal Medicine 2014, 174: 481-482. PMID: 24590098, DOI: 10.1001/jamainternmed.2013.13685.Peer-Reviewed Original Research
2013
Contraindicated Initiation of β-Blocker Therapy in Patients Hospitalized for Heart Failure
Dharmarajan K, Masoudi FA, Spertus JA, Li SX, Krumholz HM. Contraindicated Initiation of β-Blocker Therapy in Patients Hospitalized for Heart Failure. JAMA Internal Medicine 2013, 173: 1547-1549. PMID: 23797379, PMCID: PMC4043342, DOI: 10.1001/jamainternmed.2013.7717.Peer-Reviewed Original ResearchPatterns of Change in Nesiritide Use in Patients With Heart Failure How Hospitals React to New Information
Partovian C, Li SX, Xu X, Lin H, Strait KM, Hwa J, Krumholz HM. Patterns of Change in Nesiritide Use in Patients With Heart Failure How Hospitals React to New Information. JACC Heart Failure 2013, 1: 318-324. PMID: 24621935, PMCID: PMC5322944, DOI: 10.1016/j.jchf.2013.04.005.Peer-Reviewed Original ResearchConceptsHeart failureNesiritide useHospital characteristicsHospital groupDecompensated heart failureProportion of hospitalizationsPatterns of changeMultivariate regression analysisPatient characteristicsEarly reliefHospital patternsHospitalTeaching statusPremier databaseMedical evidenceHospitalizationPatientsRegression analysisSafety concernsLow usersUse ratesGroupFailureFurther researchDyspneaUse of Niacin in the United States and Canada
Jackevicius CA, Tu JV, Ko DT, de Leon N, Krumholz HM. Use of Niacin in the United States and Canada. JAMA Internal Medicine 2013, 173: 1379-1381. PMID: 23753308, DOI: 10.1001/jamainternmed.2013.6489.Peer-Reviewed Original Research
2010
Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone
Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone. New England Journal Of Medicine 2010, 363: 2081-2084. PMID: 21083379, DOI: 10.1056/nejmp1011042.Peer-Reviewed Original Research
2008
Use of Ezetimibe in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of Ezetimibe in the United States and Canada. New England Journal Of Medicine 2008, 358: 1819-1828. PMID: 18375999, DOI: 10.1056/nejmsa0801461.Peer-Reviewed Original ResearchConceptsLipid-lowering agentsLow-density lipoprotein cholesterolLipid-lowering guidelinesRatio of prescriptionsUse of ezetimibeTreatment of hyperlipidemiaStatin useCohort studyLipoprotein cholesterolSecondary preventionStatin prescriptionClinical outcomesPrescribing practicesEzetimibeIMS HealthUnited StatesPrescriptionMonthly numberFirst optionDistinct patterns
2004
National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2004, 110: 724-731. PMID: 15289383, DOI: 10.1161/01.cir.0000138934.28340.ed.Peer-Reviewed Original ResearchConceptsACE inhibitor prescriptionAngiotensin receptor blockersVentricular systolic dysfunctionHeart failureACE inhibitorsInhibitor prescriptionSystolic dysfunctionOlder patientsLeft ventricular systolic dysfunctionAngiotensin converting enzyme (ACE) inhibitorsSerum creatinine levelsACE inhibitor useCreatinine levelsHospital factorsInhibitor useReceptor blockersSerum creatininePatient genderClinical trialsTherapeutic substitutionLower riskEnzyme inhibitorsLower mortalityPatientsSecondary analysisAssociation Between Functional Status and Use and Effectiveness of Beta‐Blocker Prophylaxis in Elderly Survivors of Acute Myocardial Infarction
Vitagliano G, Curtis JP, Concato J, Feinstein AR, Radford MJ, Krumholz HM. Association Between Functional Status and Use and Effectiveness of Beta‐Blocker Prophylaxis in Elderly Survivors of Acute Myocardial Infarction. Journal Of The American Geriatrics Society 2004, 52: 495-501. PMID: 15066062, DOI: 10.1111/j.1532-5415.2004.52153.x.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAcute DiseaseAdrenergic beta-AntagonistsAge FactorsAgedAged, 80 and overCross-Sectional StudiesDrug PrescriptionsDrug UtilizationFemaleGeriatric AssessmentHumansLogistic ModelsMaleMultivariate AnalysisMyocardial InfarctionPatient DischargePatient SelectionPractice Patterns, Physicians'Proportional Hazards ModelsRetrospective StudiesSurvival AnalysisTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionHospital dischargeFunctional impairmentElderly patientsMyocardial infarctionAcute myocardial infarction survivorsBeta-blocker prescriptionBeta-blocker prophylaxisBeta-blocker treatmentRetrospective cohort studySimilar survival benefitMain outcome measuresMyocardial infarction survivorsAcute care hospitalsEligible patientsCohort studySurvival benefitCare hospitalFunctional statusNational cohortInfarction survivorsOutcome measuresElderly survivorsPatientsCognitive impairment
2003
Improving diagnostic testing and reducing overuse of antibiotics for children with pharyngitis: a useful role for the electronic medical record
BENIN AL, VITKAUSKAS G, THORNQUIST E, SHIFFMAN RN, CONCATO J, KRUMHOLZ HM, SHAPIRO ED. Improving diagnostic testing and reducing overuse of antibiotics for children with pharyngitis: a useful role for the electronic medical record. The Pediatric Infectious Disease Journal 2003, 22: 1043-1047. PMID: 14688562, DOI: 10.1097/01.inf.0000100577.76542.af.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnti-Bacterial AgentsChildChild, PreschoolDiagnostic Tests, RoutineDrug Resistance, MultipleDrug UtilizationElectronic Data ProcessingFemaleHumansLogistic ModelsMalePharyngitisProbabilityRegistriesRetrospective StudiesRisk AssessmentSensitivity and SpecificitySeverity of Illness IndexStatistics, NonparametricConceptsElectronic medical recordsOveruse of antibioticsDiagnostic testingMedical recordsEpisode of pharyngitisPediatric outpatient settingProportion of episodesOutpatient settingAntibiotic useScarlet feverPharyngitisChildren 3Diagnostic testsPatientsAntibioticsAppropriate useCliniciansWeeksEpisodesOveruseUseful rolePrescribingFeverClinicTestingWhat Are Hospitals Doing to Increase Beta-Blocker Use?
Bradley EH, Holmboe ES, Wang Y, Herrin J, Frederick PD, Mattera JA, Roumanis SA, Radford MJ, Krumholz HM. What Are Hospitals Doing to Increase Beta-Blocker Use? The Joint Commission Journal On Quality And Patient Safety 2003, 29: 409-415. PMID: 12953605, DOI: 10.1016/s1549-3741(03)29049-3.Peer-Reviewed Original ResearchConceptsBeta-blocker useQuality improvement interventionsMyocardial infarctionCare coordinatorsClinical pathwayImprovement interventionsAcute myocardial infarctionCross-sectional analysisQuality improvement staffQuality improvement effortsNational registryMedian numberHospitalTelephone surveyInfarctionReminder FormInterventionImprovement effortsRegistryPrevalencePathwayPhysiciansAspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction
Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Journal Of The American College Of Cardiology 2003, 42: 201-208. PMID: 12875751, DOI: 10.1016/s0735-1097(03)00572-2.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAnalysis of VarianceAngiotensin-Converting Enzyme InhibitorsAspirinCase-Control StudiesCohort StudiesDrug Therapy, CombinationDrug UtilizationFemaleHumansKidney Failure, ChronicLogistic ModelsMaleMyocardial InfarctionPatient SelectionPeritoneal DialysisPlatelet Aggregation InhibitorsPractice Patterns, Physicians'PrognosisRenal DialysisRisk FactorsSurvival AnalysisTreatment OutcomeUnited StatesConceptsEnd-stage renal diseaseNon-ESRD patientsAcute myocardial infarctionESRD patientsRenal diseaseMyocardial infarctionAngiotensin-converting enzyme inhibitor therapyEnd-stage renal disease patientsAngiotensin-converting enzyme inhibitorStandard medical therapyEnzyme inhibitor therapyRenal disease patientsCooperative Cardiovascular Project databaseHigh-risk populationLogistic regression modelsEarly administrationInhibitor therapyMedical therapyACE inhibitorsAMI patientsPeritoneal dialysisPoor prognosisDisease patientsESRD databasePatientsCharacteristics of Physician Leaders Working to Improve the Quality of Care in Acute Myocardial Infarction
Holmboe ES, Bradley EH, Mattera JA, Roumanis SA, Radford MJ, Krumholz HM. Characteristics of Physician Leaders Working to Improve the Quality of Care in Acute Myocardial Infarction. The Joint Commission Journal On Quality And Patient Safety 2003, 29: 289-296. PMID: 14564747, DOI: 10.1016/s1549-3741(03)29033-x.Peer-Reviewed Original ResearchAdrenergic beta-AntagonistsAttitude of Health PersonnelCardiology Service, HospitalClinical CompetenceDrug UtilizationHospital AdministratorsHumansInterdisciplinary CommunicationInterviews as TopicLeadershipMedical Staff, HospitalMyocardial InfarctionNursing Staff, HospitalQualitative ResearchTotal Quality ManagementUnited StatesEffects of age on the quality of care provided to older patients with acute myocardial infarction
Rathore SS, Mehta RH, Wang Y, Radford MJ, Krumholz HM. Effects of age on the quality of care provided to older patients with acute myocardial infarction. The American Journal Of Medicine 2003, 114: 307-315. PMID: 12681459, DOI: 10.1016/s0002-9343(02)01531-0.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAge FactorsAgedAged, 80 and overAttitude of Health PersonnelCohort StudiesCombined Modality TherapyCoronary Care UnitsCritical CareDrug UtilizationFemaleGuideline AdherenceHealth Services AccessibilityHealth Services for the AgedHumansLogistic ModelsMaleMedicareMyocardial InfarctionOdds RatioPractice Patterns, Physicians'Quality of Health CareRisk AssessmentSurvival AnalysisThrombolytic TherapyUnited StatesConceptsAcute reperfusion therapyAcute myocardial infarctionMyocardial infarctionReperfusion therapyEffect of ageElderly patientsOlder patientsAge-associated variationsGuideline-recommended medical therapyAngiotensin-converting enzyme inhibitorGuideline-indicated therapiesPrescription of aspirinUse of aspirinCooperative Cardiovascular ProjectUse of therapiesQuality of careAcute reperfusionTreatment contraindicationsMedical therapyComorbid conditionsACE inhibitorsMedicare patientsHospital effectsPatientsEnzyme inhibitors
2001
Physician characteristics and the initiation of beta-adrenergic blocking agent therapy after acute myocardial infarction in a managed care population.
Fehrenbach SN, Budnitz DS, Gazmararian JA, Krumholz HM. Physician characteristics and the initiation of beta-adrenergic blocking agent therapy after acute myocardial infarction in a managed care population. The American Journal Of Managed Care 2001, 7: 717-23. PMID: 11464429.Peer-Reviewed Original ResearchConceptsBeta-adrenergic blocking agentsAcute myocardial infarctionBeta-adrenergic blocking agent therapyRegion of hospitalizationFamily practice physiciansPhysician characteristicsBlocking agentMyocardial infarctionHospital dischargeAgent therapyPractice physiciansPercent of patientsRetrospective administrative data analysisPatient agePatient characteristicsMedication claimsStudy cohortCare populationCardiac treatmentAdministrative data analysisInfarctionMultivariate modelPhysiciansHospitalizationCare organizations